Who We Are
Epigenetic Data Science (EDS) was established on the belief that the conventional models for exploring breakthroughs in the fight against cancer have not realized their full potential. (Learn details about the personal family story of our founder, Andrew Pollack.)
Genetic, epigenetic, and gene expression knowledge is being generated daily in thousands of laboratories and universities worldwide. EDS has created an innovative system to consolidate this data, and our team is hard at work analyzing and determining the distinct genes involved in breast cancer formation and progression. Our database and techniques will be used for other types of cancer, Alzheimer’s, dementia, and autoimmune diseases in the near future.
EDS serves as the ultimate environment where scientific collaboration stretches across disciplines. Our researchers have the intellectual freedom to challenge the status quo, and their grand visions for breakthroughs in human health inspire a collective drive to achieve the seemingly impossible.
We strive to open a new front on the war on cancer by leveraging the vast amount of genetic and epigenetic data generated worldwide. Then, we apply that knowledge to carefully orchestrate the expression of over one hundred genes associated with cancer.
The traditional model of targeting just one or two genes is not the most effective, as research has determined that cancer relies on hundreds of genes working in concert to grow and metastasize. Our EDS team is breaking the mold with our targeted approach that is designed to attack cancer cells from every aspect.
Data science has evolved to give us the tools required to process hundreds of thousands of research findings, and by applying those tools, we can now open a much broader attack on cancer.
The launch of the Indigo supplement protocol is the summation of our research as of today.
More information can be found at Elsie Genetics, a division of EDS.
We wish you the best as you continue the fight
and hope that our work plays a part in improving your life.